SECTORS

Health & Life Sciences

Meeting the Challenge of BioPharma: New Pathways to Innovation

In the high-stakes field of life science innovation, maximizing clinical and commercial value requires understanding opportunity, managing risk, and taking bold action at milestone moments. Marketing functions have had to adapt to an environment where greatest unmet need and opportunity lie with targeted therapies for smaller populations – and the quality of customer insights has never been more important. At the same time, the quantity of data available and the tools to deploy it have also never been more exciting. We have powerful new statistical sightlines to patient journey mile posts, clinical decision drivers, and health outcomes that open up vistas unimagined before the data science revolution spawned by AI.

The ability to predict more accurately and the agility to pivot faster are critical success drivers, which means that life science innovators need to marshal all the data at their disposal.

For the Life of Your Brand, From Launch through Healthy Maturity

With a 50-year track record of commercialization support, NAXION has had a hand in well over 70 drug launches, including treatments that revolutionized healthcare.

NAXION’s specialized NAscence Group helps commercialization teams make confident decisions at each step along the development path. In working to bring novel compounds and platform technologies to market, we’ve partnered with some of biotech’s most innovative startups as well as the industry’s leading global players to help change the standards of medical care. Our NAscence practice draws on the resources of the broader firm and some of the industry’s most experienced life science insights professionals to support the innovation process, from pre-clinical through launch and beyond.

We also support clients throughout the patent life cycle by helping them pursue supplemental indications, publication strategy, portfolio positioning, and brand positioning refresh to maximize the resilience and commercial lifetime value of their brands.

The building blocks of our decision support reflect unique “enterprise DNA” – the fusion of highly skilled methodology with exceptionally broad life science experience and the inventiveness to apply those tools in new ways.

  • Deep clinical expertise in a broad range of disease categories, including extensive track records in immuno-oncology and rare/ultra-rare disease markets
  • Hands-on senior oversight of every assignment, no matter the size, and highly consultative teams with marketing acumen to match their research expertise
  • Flexible, cost-effective support for emerging biotechs with little or no commercial infrastructure
  • Proficiency in a broad range of methods, qualitative as well as quantitative, to extract and synthesize insights from multiple data streams and perspectives
  • Talented staff moderators with a specialized healthcare focus, promoting depth of insight and patient-centric inspiration
  • Robust, customized predictive models to guide clinical trials design and build forecasts
  • In-house data science expertise to spot critical patient journey intervention points, understand market drivers, and find undertreated patients and therapy candidates

Portfolio of Services and Techniques Customized for the Life Sciences

Our role in shaping the insights discipline is reflected in a toolkit that is rigorous, versatile, and readily adapted for distinct challenges. Attesting to our exceptional rigor and sophistication is a body of work that has helped the FDA to exercise its public policy mandate and studies of patients and physicians robust enough for peer-reviewed publication in medical and public health journals. Our contributions to the body of knowledge in healthcare marketing are supported by an expert toolkit adapted to the distinct challenges posed by life science innovation.

  • Vivid patient journey maps that tap and merge multiple data streams for predictive accuracy and rich insight
  • Highly customized Farsight® forecast models designed to accommodate multiple stakeholders and varied market contingencies
  • Sensitive choice and driver models built to measure the value of critical market differentiators, even small ones
  • Best-in-class brand performance tracking programs designed to be prognostic as well as diagnostic
  • Advanced Insightline® secondary data analytics for an integrative approach to insight generation
  • Effective use of curated AI tools to enhance the efficiency of qualitative and quantitative analysis without compromising the yield